PTC299

1256565-36-2

C25H20Cl2N2O3

DMSO : 50 mg/mL (106.99 mM; Need ultrasonic)

Protein Tyrosine Kinase/RTK

PTC299 is a potent, orally bioavailable VEGFA inhibitor, targets dihydroorotate dehydrogenase (DHODH), resulting in cell growth inhibition and differentiation in leukemias, including acute myeloid leukemia, linking DHODH regulation and stress-induced VEGFA and angiogenesis^[1][2][3]. IC50 & Target: VEGF^[2] In Vitro: PTC299 inhibits hypoxia-induced VEGFA protein production in HeLa cells with an EC₅₀ of 1.64 +/- 0.83 nM^[1].
PTC299 is the most potent inhibitor with an IC₅₀ of about 1 nM, over 10 to 1000-fold more potent than Brequinar, Vidofludimus or A 77-1726 in leukemia cells^[1].